Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy. (Q39152306)
Jump to navigation
Jump to search
scientific article published on March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy. |
scientific article published on March 2013 |
Statements
Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy (English)